News

Weill Cornell Medicine recently hosted the New York Pathological Society's Fall Mini-Symposium. 

Weill Cornell Medicine and Champions Oncology signed a licensing agreement allowing Champions Oncology to distribute and commercialize Weill Cornell Medicine’s extensive bank of hematological PDX models

Though using large language models (LLM) that drive artificial intelligence (AI) to draft patient notes shows promise in saving physicians time, they will still need to review and edit these summaries for accuracy, finds a new study by researchers at Weill Cornell Medicine. 

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.

Many individuals seeking asylum in the United States show increased stress and pain symptoms that are associated with indications of cardiovascular disease, according to Weill Cornell Medicine researchers.

Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Korea’s Yonsei University. 

USF Health and Weill Cornell Medicine researchers have published the first version of their clinically validated voice dataset to an online artificial intelligence platform to serve as an invaluable resource for investigators across the globe.  

Weill Cornell Medicine has recently promoted longtime institutional leaders Thomas W. Stokes, Michael T. Murphy and Eric M. Saidel to elevated administrative posts.

Increasing the levels of chemicals naturally produced in the body called endocannabinoids may thwart the highly addictive nature of opioids such as morphine and oxycodone while maintaining the drugs’ ability to relieve pain, according to a new preclinical study by Weill Cornell Medicine investigators.

Severe COVID-19 arises in part from the SARS-CoV-2 virus’s impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging events, suggests a study by investigators at Weill Cornell Medicine, Johns Hopkins Medicine, Children’s Hospital of Philadelphia, and the University of Pittsburgh School of Medicine, along with other members of the COVID-19 International Research Team.

Inhibiting an immune signaling protein called TLR7 may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer’s disease and ordinary aging, suggests a study led by researchers at Weill Cornell Medicine.

A fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators. 

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

 Awards, honors and achievements for the month of November.

The secret to cellular youth may depend on keeping the nucleolus—a condensed structure inside the nucleus of a cell—small, according to Weill Cornell Medicine investigators. The findings were elucidated in yeast, a model organism famous for making bread and beer and yet surprisingly similar to humans on the cellular level.

Working with week-old zebrafish larva, researchers at Weill Cornell Medicine and colleagues decoded how the connections formed by a network of neurons in the brainstem guide the fishes’ gaze.

With just one slide and three minutes, fourth-year graduate student Erin Keblish described how she is developing a carbon nanotube-based sensor that could act like a “smoke detector” for early signs of deadly sepsis, during Weill Cornell Medicine’s ninth annual Three-Minute Thesis (3MT®) competition on November 13.

A novel combination of surgery and embolization used to treat subdural hematomas, bleeding between the brain and its protective membrane due to trauma, reduces the risk of follow-up surgeries, according to researchers at Weill Cornell Medicine and University at Buffalo.

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

The center connects health policy researchers across Cornell’s campuses to help shape effective health policy at the federal, state and local levels.